Literature DB >> 7600915

Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats.

D M Ouellet1, G M Pollack.   

Abstract

Morphine elimination is characterized by a prolonged terminal elimination phase, at least in part because of enterohepatic recirculation (EHR) of morphine as its major metabolite, morphine-3-glucuronide (M3G). This experiment was conducted to characterize M3G disposition after direct administration of the metabolite to intact or bile duct-cannulated (BC) rats, and to develop a pharmacokinetic model of EHR for M3G. Male Sprague-Dawley intact and BC rats (N = 4/group) received a 5 mg/kg iv bolus of M3G, with serum and bile sampled at timed intervals after the dose; urine was collected in toto at the end of the experiment. M3G elimination from serum was rapid in BC rats; in contrast, M3G residence was prolonged in intact animals. M3G biliary excretion rate vs. time profiles paralleled the M3G serum concentration-time profiles in BC rats, with up to 20% of the dose recovered as M3G in bile. The remainder of the dose (80%) was recovered in urine as unchanged M3G. No morphine could be detected in urine after M3G administration. To confirm that biliary elimination of M3G occurred following uptake by the liver, M3G was administered to isolated perfused rat livers (N = 4). Up to 20% of the M3G dose was recovered in bile after 90 min, suggesting that systemic M3G can gain access to the liver and contribute to EHR. Both mean residence time and steady-state volume of distribution were significantly greater in intact rats, presumably because of EHR.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7600915

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat.

Authors:  S P Letrent; G M Pollack; K R Brouwer; K L Brouwer
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

Review 3.  Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity.

Authors:  Brandon Swift; Nathan D Pfeifer; Kim L R Brouwer
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

4.  Extensive biliary excretion of the model opioid peptide [D-PEN2,5] enkephalin in rats.

Authors:  C Chen; G M Pollack
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

5.  In vivo-formed versus preformed metabolite kinetics of trans-resveratrol-3-sulfate and trans-resveratrol-3-glucuronide.

Authors:  Satish Sharan; Otito F Iwuchukwu; Daniel J Canney; Cheryl L Zimmerman; Swati Nagar
Journal:  Drug Metab Dispos       Date:  2012-07-17       Impact factor: 3.922

6.  Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.

Authors:  Tae Hwan Kim; Soyoung Shin; Cornelia B Landersdorfer; Yong Ha Chi; Soo Heui Paik; Jayhyuk Myung; Rajbharan Yadav; Stefan Horkovics-Kovats; Jürgen B Bulitta; Beom Soo Shin
Journal:  AAPS J       Date:  2015-05-20       Impact factor: 4.009

7.  Pharmacokinetics and bioavailability of the isoflavone biochanin A in rats.

Authors:  Young Jin Moon; Kazuko Sagawa; Kosea Frederick; Shuzhong Zhang; Marilyn E Morris
Journal:  AAPS J       Date:  2006-07-07       Impact factor: 4.009

8.  Morphine antinociception is enhanced in mdr1a gene-deficient mice.

Authors:  J Zong; G M Pollack
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

9.  Population Pharmacokinetic Modelling of Morphine, Gabapentin and their Combination in the Rat.

Authors:  Theodoros Papathanasiou; Rasmus Vestergaard Juul; Charlotte Gabel-Jensen; Mads Kreilgaard; Trine Meldgaard Lund
Journal:  Pharm Res       Date:  2016-07-05       Impact factor: 4.200

10.  Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.

Authors:  Islam R Younis; Samuel Malone; Henry S Friedman; Larry J Schaaf; William P Petros
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-22       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.